Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Merkel Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 4Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1

Interventions

radium Ra 223 dichloride 1peposertib 1avelumab 1Specimen Handling 1PITX2 protein, human 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphatic Metastasis × avelumab × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡